Phase IIb data scratch the itch for Creabilis
Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.
Creabilis has reported positive Phase IIb data from with its lead anti-itch product CT327, a novel topical TrkA kinase inhibitor, in psoriasis patients, although not all study endpoints were met.